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Aim: To provide an assessment of published literature on the demographic representation in Phase I trials
of biopharmaceutical oncology agents. Materials & methods: We conducted a rapid evidence assessment
to identify demographic representation reported in Phase I clinical trials for biopharmaceutical oncology
agents published in 2019. Results: Globally, the population was predominantly White/Caucasian (62.2%).
In the USA, the distribution was heavily skewed toward White/Caucasian (84.2%), with minimal representation of Blacks/African–Americans (7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or other race/ethnicity
groups. Conclusion: Our data highlight that Phase I oncology trials do not reflect the population at large,
which may perpetuate health disparities. Further research is needed to understand and address barriers
to participation, particularly among under-represented groups
Lay abstract: A plain language version of this article is available and is published alongside the paper
online: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-1262
First draft submitted: 14 December 2020; Accepted for publication: 27 April 2021; Published online:
28 May 2021
Keywords: clinical trial • disparities • ethnicity • oncology • Phase I • race

Clinical trials provide answers to scientific questions that enable global regulatory agencies (i.e., the US FDA and
the EMA) to evaluate the safety and efficacy of novel therapeutics, inform medical professionals on the use of new
therapeutic agents, and make approval decisions. Clinical trial participation provides benefits both for participants
and for informing drug development to improve treatment options for patients. It is important that clinical trials
provide evidence regarding pharmacokinetics/pharmacodynamics, safety and efficacy of investigational treatments
across different demographic populations. An important consideration in drug development is addressing health
disparities (defined by Healthy People 2020 as ‘a particular type of health difference that is closely linked with
social, economic and/or environmental disadvantage’) [1] which exist among racial or ethnic minority groups. These
disparities can include health outcomes influenced by unequal access to health insurance, as well as differences in the
incidence [2] and survival rates [3] for people with cancer. For example, there is a disproportionately higher incidence
of multiple myeloma, colorectal cancer, triple negative breast cancer and prostate cancer in African–Americans,
gastric cancer in Asians and Pacific Islanders, and cervical cancer in Hispanic and American–Indian/Alaska Native
women [2]. Hence, there is a compelling need for clinical trials including oncology trials, to have an equitable
representation of diverse racial and ethnic groups rather than the current over-representation of non-Hispanic
White individuals.
A study published in 2018 reported on the racial/ethnic composition of individuals participating in biobanks,
genomic studies and clinical trials [4]. Of patient-provided oncological samples, data on the donor’s race/ethnicity
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was not reported (NR) for 48.3% of samples, and remaining specimens were from White (37.5%), Asian (10.0%),
African–American (3.8%) and Hispanic (0.4%) donors. Of particular note is that among 416 cancer-related
genome-wide association studies including more than 6.3 million samples, 92% of the samples were obtained from
people of European descent [4]. This trend calls into question whether the effectiveness and safety of investigational
drugs are tested in a broader percentage of the population that will eventually use the approved drug.
The FDA Safety and Innovation Act of 2012 (FDASIA) [5] directs the FDA to investigate the demographic
representation (sex, age, race and ethnicity) of applications for medical products for both inclusion in clinical trials
and for subgroup-specific safety and effectiveness data. Section 907 of the Act focused 27 actionable items into three
priorities, which aim to increase the completeness and quality of demographic subgroup data, improve the public
availability of demographic subgroup data, identify barriers to subgroup enrollment in clinical trials, and employ
strategies to encourage greater participation. Additionally, in June 2019, under Section 610(a)(3) of the FDA 26
Reauthorization Act of 2017 (FDARA) (21 U.S.C. 360bbb note) [6], the FDA issued draft guidance to broaden
eligibility criteria in clinical trials for drugs intended to treat rare diseases or conditions so as to avoid unnecessary
population exclusions from clinical trials, develop eligibility criteria and improve clinical trial recruitment [7]. The
overall aim of these measures is for participants enrolled in clinical trials to better reflect the population most likely
to use the drug, if approved, while maintaining safety and effectiveness standards.
Although guidance has been introduced to increase the inclusion of racial/ethnic minorities in clinical trials,
participation in oncology trials by individuals with these demographics remains low. For example, in 2019, 3593
patients participated in clinical trials used to generate evidence for FDA submissions for oncology drugs, resulting
in the approvals of 11 new oncology therapeutics. Of these, the majority of participants were male (62%) and
White (73%), as compared with Asian (18%), Black or African–American (4%), and Hispanic (5%). Just over half
of participants (59%) were ≥65 years and approximately one quarter (24%) of participants were from US-based
enrollment sites [8].
Eligible participants in Phase I oncology trials generally have advanced disease, with limited or no evidence-based
treatments available [9], and inclusion in such trials is of benefit to a wide patient demography. Better representation
of the population at large in Phase I trials should allow assessment of drug candidates in populations that are likely
to receive the drug when marketed.

Objective

This manuscript reports a summary from a rapid evidence assessment (REA) of recently published Phase I clinical
trials in clinical oncology. The primary objective of the REA was to conduct a descriptive assessment of published
literature on the demographic representation in Phase I clinical trials of biopharmaceutical oncology agents.
Materials & methods
Search strategy
This REA was guided according to the principles of the Interim Guidance from the Cochrane Rapid Reviews
Methods Group [10] and guidance from the University of York Centre for Reviews and Dissemination [11]. The
REA employed a standardized, systematic and transparent approach to identify, describe, report and interpret
published evidence in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Protocol guidelines and as described in an a priori study protocol (unpublished). The search strategy was designed
to identify current literature (published between January and December 2019) that reported the demographic
representation of individuals recruited for Phase I clinical trials for biopharmaceutical oncology agents. Searches
R
via
were run on 18 December 2019 in the following literature databases, for publications in English: Embase
R

Ovid, MEDLINE (including in-process citations, etc.) via Ovid and PubMed. The full search strategy and
number of identified hits for each database are presented in Supplementary Appendix 1.
Selection criteria & screening

The population, intervention, comparator, outcomes and study types included in the REA are described in Table 1.
Publications that met the criteria described in Supplementary Appendix 2 were excluded. These included nonEnglish publications, congress abstracts, studies of benign hematologic disorders, and reviews or meta-analyses.
One reviewer (K Smoyer) screened the titles and abstracts (level 1) of the references identified in the database
searches against study inclusion/exclusion criteria; a second reviewer (C Rolland) conducted a 20% cross-check to
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Table 1. Inclusion criteria.
PICOS criteria

Inclusion criteria

Population

Patients ≥18 years of age, with any solid tumor or hematological malignancy or healthy volunteers

Intervention

Any biopharmaceutical agent investigated for the treatment of cancer

Comparator

Any or none

Outcomes

Any

Study design

Phase I, Ia or Ib prospective interventional studies

Time period

Published in the peer-reviewed literature between 1 January and 31 December 2019

PICOS: Population, intervention, comparator, outcomes and study type.

validate the screening. The same process was applied for the full-text (level 2) screen of the papers identified in level
1, including a 20% validation by a separate reviewer (C Rolland). Disagreements were discussed until consensus,
or a third reviewer (I Jacobs, LJ Lee or J McGinnis) was consulted to make the final inclusion/exclusion decision.
Data extraction & reporting

One reviewer (G Bowden) extracted the data from the included manuscripts into a prespecified data extraction form,
and a second reviewer (K Smoyer) validated 100% of the extractions. Discrepancies were resolved by consulting
the original manuscript. Missing data were coded as ‘not reported’. Data are reported as a whole for all trials and
stratified by three main regions as follows: the USA only, mixed (USA + ≥1 other country) and USA-excluded (any
country other than the USA). Due to a relatively homogeneous population (90% or more Asian ethnic groups, or
classified as ‘homogenous’ according to the CIA Factbook) [12], all participants in trials from the following single
countries were classified as Asian if not otherwise specified: China, Japan, South Korea, Taiwan and Vietnam.
Details of the data extraction and classification into regions are provided in Supplementary Appendix 3.
Patient counts for each demographic group were summed across the included Phase I trials and for the three
regions. Data were tabulated for all participants, patients only and healthy volunteers, and are reported at the
clinical trial level as well as the population level. The results presented here, however, mainly focus on those from
clinical trials conducted in patients in the USA, in order to assess demographic representation in accordance with
FDA guidance [5].
Results
Clinical trial characteristics

Out of 1431 references identified from the literature searches and undergoing title/abstract screening, 381 were
retained for full-text screening, and 1050 were excluded. After full-text screen of 381 papers, 374 papers were
included with a combined total of 16,763 participants. A complete list of included papers is provided in Supplementary Appendix 4. A summary of results from the database searches and publication selection process is presented
in Figure 1. Characteristics of the included trials are summarized below (Table 2).
The proportion of males and females across all trials was balanced (48.7 and 47.7%, respectively). Gender was NR
or not available in 13 (3.5%) studies, comprising 613 participants. Race or ethnicity was identified in 220 (58.8%) of
the 374 Phase I oncology clinical trials assessed in this review, encompassing a total of 9972 participants. Among the
220 clinical trials with demographic data, the population was predominantly White/Caucasian (62.2%) (Table 3).
Asian participants (29.9%) were predominantly from studies conducted in Asian countries (all participants classified
as Asian). Black participants (3.9%) and Hispanic/Latino participants (1.2%) were under-represented.
US-only trials

A total of 139 trials was conducted in the USA only; 137 of these were in patients and two trials were in
healthy subjects. Of the subset of Phase I oncology trials conducted in US patients, 64.2% reported race/ethnicity,
representing 3197 patients. The distribution of patients in US trials was heavily skewed toward Whites (84.2%),
with minimal representation of Blacks/African–Americans (7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or
other race/ethnicity groups among the trials that reported race or ethnicity data (Table 4). Blacks and Hispanics,
who account for an estimated 13.4 and 18.3% of the total US population, respectively, were under-represented
in the clinical trials identified in this study, even though age-adjusted cancer rates are comparable to Whites.
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Records identified through
Medline (n = 1213)
EMBASE (n = 1091)
PubMed (n = 1218)
Total (n = 3522)

Identification

Systematic Review

Duplicates removed
(n = 2091)

Screening

Titles and abstracts screened: level 1
(n = 1431)

Excluded at level 1 (n = 1050)
Not population of interest: 9
Not intervention of interest: 153
Not outcome of interest: 21
Not study design of interest: 446
Not publication type of interest: 336
Duplicates: 85

•
•
•
•
•

Excluded at level 2 (n = 7)
Not population of interest: 2
Not intervention of interest: 1
Not outcome of interest: 1
Not publication type of interest: 1
Duplicate: 2

Included

Eligibility

Full text screened: level 2
(n = 381)

•
•
•
•
•
•

Figure 1.
process.

Included publications
(n = 374)

Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of publication selection

Table 2. Characteristics of Phase I oncology trials.
Trial characteristic

Studies (n = 374), n (%)

Phase I studies

374 (100.0)

– Studies in patients

367 (98.1)

– Studies in healthy subjects

7 (1.9)

First in human studies

89 (23.8)

Demographic characteristics
– Race/ethnicity reported

220 (58.8)

– Gender reported

361 (96.5)

Geography of trials
– US population only

139 (37.2)

– Ex-US population only

150 (40.1)

– Mixed US and ex-US population

79 (21.1)

– Unable to determine

6 (1.6)

Cancer type
– Solid malignancies

297 (79.4)

– Hematological malignancies

58 (15.5)

– Solid + hematological malignancies

12 (3.2)

– Conducted in healthy subjects

7 (1.9)

Solid malignancies: e.g., breast, lung colorectal, prostate, gastric and so on. Hematological malignancies: e.g., multiple myeloma, lymphomas, leukemias and so on.
Ex-US: the USA-excluded.
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Table 3. Race/ethnicity of participants in Phase I clinical trials in oncology: all regions globally.
Race/ethnicity

All participants (n = 9972), n (%)

Patients (n = 9550), n (%)

Total with race or ethnicity reported

9972 (100.0)

9550 (100.0)

White/Caucasian

6198 (62.2)

6056 (63.4)

Black/African–American

388 (3.9)

371 (3.9)

Asian

2986 (29.9)

2734 (28.6)

Native Hawaiian/Pacific Islander

8 (0.1)

5 (0.1)

American–Indian/Native Alaskan

11 (0.1)

10 (0.1)

More than one race

11 (0.1)

4 (⬍0.1)

Other/unknown

321 (3.2)

321 (3.4)

Hispanic/Latino†

115 (1.2)

113 (1.2)

† Some

studies reported Hispanic/Latino as a race category and some as an ethnicity; as a result the sum of participants by race/ethnicity category is greater than the total number of
participants.

Table 4. Race/ethnicity of US patients in Phase I clinical trials in oncology compared with US demographics and cancer
incidence.
US patients (%)

US Census† (%)

SEER data‡ : 2013–2017 age-adjusted
cancer incidence per 100,000

White/Caucasian

84.2

76.5

452.1

Black/African–American

7.3

13.4

440.4

Asian

3.4

5.9

302.0§

Native Hawaiian/Pacific Islander

0.1

0.2

NR§

American–Indian/Native Alaskan

0.1

1.3

310.1

More than one race

0.0

2.7

NR

Other/unknown

3.7

–

NR

Hispanic/Latino

2.8

18.3

348.4

Race/ethnicity

† Source:

US Census Bureau. Population Estimates, July 2019 (https://www.census.gov/quickfacts/fact/table/US).
‡ Source: Surveillance, Epidemiology and End Results (SEER) Program. 5-Year age-adjusted incidence rates, 2013–2017 for all cancers (https://seer.cancer.gov/explorer/).
§ Hawaiian/Pacific Islander included with Asian.
NR: Not reported; SEER: Surveillance, Epidemiology and End Result.

Participation of Native Hawaiian/Pacific Islander and American–Indian/Native Alaskan patients was extremely
low.
Discussion
Our review of the literature published in 2019 found the demographic composition of the 220 Phase I oncology
clinical trials (n = 9972), for which race or ethnicity was identifiable, to be predominantly White/Caucasian (62.2%),
followed by Asian (29.9%). For clinical trials conducted in the USA only, and the main focus for this report, the
distribution was heavily skewed toward Whites (84.2%), with minimal representation of Blacks/African–Americans
(7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or other race/ethnicity groups among the trials that reported
race or ethnicity data. Despite the introduction of FDA guidance to increase enrollment of under-represented
groups in clinical trials, the results of this REA indicate that participation in recent Phase I oncology trials by
individuals with these demographics remains low. Because patients in Phase I trials may potentially experience
therapeutic benefits [13], inclusion of a broader patient population in Phase I trials can help ensure that diverse
groups, regardless of race or ethnicity, benefit from new treatment options.
This review of Phase I trials published in 2019 further showed that the imbalance in racial representation
in oncology trials observed at later phases continues to exist in earlier phase trials. This can lead to Phase I
oncology trials that are not representative of the population most likely to benefit from new cancer treatments.
The demographic findings of the current study are similar to a study by Ramamoorthy et al. of Phase I–III pivotal
trials of drugs approved by the FDA between 2008 and 2013 for breast, colorectal, lung or prostate cancer [14].
In those trials, 79.7% of patients were White, 12.4% Asian and 3.8% Black/African–American; Hispanic/Latinos
comprised 3.6% of patients in the included trials [14]. Our findings are also similar to those of a recent study by
Loree et al. of clinical trials leading to FDA approvals for cancer drugs between 2008 and 2018, which reported

future science group

www.futuremedicine.com

3275

Systematic Review

Camidge, Park, Smoyer et al.

that 63% provided data on at least one racial group, with Whites representing 76.3%, Asians 18.3%, Blacks 3.1%
and Hispanics 6.1% of clinical trial participants [15].
An analysis of 358 oncology trials comparing those sponsored by pharmaceutical companies versus the National
Cancer Institute’s National Clinical Trial’s Network reported that the proportion of Black patients was 2.9% for
pharmaceutical company-sponsored trials and 9.0% for National Clinical Trial’s Network trials, significantly lower
than their calculation that estimated that 12.1% of the US cancer population are Black (the calculation was based
on an adjusted analysis of Surveillance, Epidemiology and End Results data to reflect the US cancer population by
weighting estimates based on national distributions of age, sex and race using US Census data). The findings were
generally consistent across individual cancer types [16].
The lack of racial representation may perpetuate health disparities due to the disproportionately higher incidence
of certain cancers among non-White, non-Hispanic populations. African–American males develop cancer 25%
more frequently than White males and have a 43% higher mortality rate compared with White men for all cancers
combined [17]. Furthermore, according to the CDC, African–American men “have more cancers of the lung,
prostate, colon and rectum than do White men. Overall, African–American men have more malignant tumors and
are less likely to survive cancer than the general population” [17], further highlighting the importance for higher
inclusion of African–Americans and other demographic groups in Phase I oncology trials to better reflect the
populations that are most likely to benefit from a drug. Our REA provides an initial broad look at demographic
representation across recently published Phase I oncology trials within defined parameters. Future analyses could
include additional considerations such as reporting on the number of studies that request biomarker or targeted
mutation analyses for preselection, and if this varies by race for example.
Race/ethnicity was NR in over 40% of the Phase I oncology trial publications included in our analysis; without
this information, it was not possible to assess demographic representation in those trials. A lack of reporting impedes
efforts to increase diversity and serves to perpetuate the status quo. When collecting race/ethnicity data, the use
of a standardized method should be encouraged, and ideally self-reported versus investigator assessed (also see
Standards for maintaining, collecting, and presenting federal data on race and ethnicity) [18]. Publications should
be more explicit and conscientious when reporting race and other useful demographic data. Equitable demographic
representation is particularly important in clinical trials of cancers with racial/ethnicity differences in incidence
and/or survival; however, sizable disparities in participation persist. All-cause cancer rates in the USA are high for
African–Americans and are only slightly lower than for Whites [19]. A greater presence of African–Americans in
oncology trials is needed to identify whether novel therapeutics show efficacy in this population, as well as to assess
their safety profiles.
A lack of racial representation in oncology trials is an issue that has persisted for many years. In 2006 [20] a review
of 163 Phase I participants from five major cancer centers in the USA reported that most participants were White
(88%), had health insurance (96%) and many (66%) were financially secure (household income ≥$50,000). Only
3% were African–American and 4% were uninsured. The sociodemographic characteristics of the patients were
similar to the characteristics of participants from other Phase I trials, but did not reflect those of the community.
For example, at the time of the analysis, 12.3% of the US population was African–American according to the
2000 US Census [21]. Part of the reason underlying the disparities in representation, in addition to health insurance
coverage/restrictions, could be due to barriers to participation in Phase I trials such as a lack of information due to
the types of institutions where patients receive care, physicians not recommending participation or not spending
enough time with patients, or patient mistrust. Also, Phase I trials, by definition, require more intensive visits,
and thus access to a higher level of medical care. In a study using focus groups and interviews of US patients and
community members in Louisiana, Davis et al. reported that although most were aware of clinical trials, they did
not know about specific trials or where to find more information [22]. Recruitment of patients is often through an
encounter with a participating physician or treatment center, which differs from healthy subject recruitment.
A qualitative study from the USA of patient visits to oncologists found that physicians spent less time with
African–American than White patients and recommended that oncologists make an effort to discuss clinical trial
participation, purpose and risks with patients, particularly African–Americans [23]. Another factor to consider is that
Medicaid is not required by federal law to provide coverage for the routine care costs for patients participating in a
clinical trial [24]. Since patients covered by Medicaid tend to be ethnic and racial minorities, women, children and
rural populations, the lack of coverage for Medicaid enrollees in clinical trials may exacerbate under-representation
of these groups in clinical trials.
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In high-risk prostate cancer, multiple randomized clinical trials have shown that definitive therapy improves
overall survival among patients. However, a recent publication reported that many patients do not receive definitive
therapy because of sociodemographic and health-related factors [25]. In an analysis of factors associated with the
receipt of nondefinitive therapy and survival among patients with high-risk prostate cancer, it was found that
compared with White patients, Black and Hispanic patients were more likely to receive only systemic therapy, or
not be treated at all. The most significant factors associated with receiving nondefinitive therapy were insurance
status, race/ethnicity, median household income, and health- and disease-related factors, including tumor stage
and medical comorbidity score [25]. In an analysis of the role of sociodemographic factors in treatment decisions
for non-small-cell lung cancer, however, socioeconomic factors rather than race/ethnicity appeared to influence
the refusal of cancer treatment in patients with stage IV non-small-cell lung cancer [26]. Various other reports have
highlighted racial or ethnic disparities in cancer incidence, treatment and outcomes, across a broad range of cancer
types [27–33].
Further research and dissemination of data highlighting the under-representation of ethnic minorities in Phase I
clinical trials should help increase awareness. In this respect, the American Society of Clinical Oncology convened
a working group, which resulted in a series of recommendations and position statement to increase participation in
Phase I trials [13,34]. The key goals of these recommendations were: improve payers’ coverage of routine patient costs
in Phase I trials, improve patients’ and clinicians’ understanding of goals of Phase I trials, increase the number of
patients who enroll in Phase I trials, increase researcher and trial sponsor compliance with best practices for Phase
I trials and increase biopharmaceutical industry support of pediatric Phase I trials. Recommendation 2 suggested
that the educational efforts of professional societies should target improving the ability of clinicians and researchers
to explain the goals of Phase I cancer trials, including how to discuss the purposes and risk-benefit assessment to
potential patient participants [13]. Recommendation 3 advised that professional societies should enhance educational
materials for clinicians and researchers to help overcome challenges to Phase I trial enrollment, such as incomplete
understanding of insurance coverage and attitudes that Phase I trials should be considered only after other treatment
options fails [13]. There is also a need for more clinicians and researchers from under-represented groups, which may
help build trust and confidence in trial participation. A recent report highlighted that although progress is being
made in this respect, much work remains to be done in increasing the number of under-represented racial/ethnic
groups in medical schools and faculty rosters [35].
This current review of Phase I trials that were published in 2019 reveals that the imbalance in racial representation
seen in later phase oncology clinical trials is also present in earlier phase trials. This period was chosen given that
it represented the most recent publications available at the time the REA was performed. Current barriers to
participation may arise due to the types of institutions where patients receive care, physicians not recommending
trials or not spending enough time with patients, health insurance coverage/restrictions, certain social determinants
of health, or patient mistrust of clinical trials. As a result, many Phase I oncology trials are not representative of the
general population, and this may perpetuate health disparities [36]. When taking the COVID-19 pandemic into
account, which has disproportionately impacted communities of color and limited access to some trials, there is the
potential for this imbalance to worsen. Conscious efforts are paramount to resolve these disparities in participation
in Phase I oncology trials, which can provide access to novel therapeutics.
There are some limitations to our analyses: for example, by observing data from trials published over just 1 year,
we were unable to track any longitudinal effects on disparities, although several other studies already discussed
corroborate our findings. The unavailability of precise information on race/ethnicity in trials conducted in Asian
countries is another limitation of this analysis and may over-represent the percentage of trials reporting race and
the percentage of Asian subjects in clinical trials globally in this region. However, this did not affect the dataset
from the USA.

Conclusion
Recruitment and retention of under-represented groups in Phase I oncology clinical trials is essential to ensure
the demographics of participants reflect the wider population at large. A targeted strategy to recruit representative
populations is needed, and further research is required in order to understand, and thus reduce, the barriers to
participation, particularly among under-represented groups.
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Future perspective
It is clear that an imbalance in racial or ethnic representation in Phase I oncology trials has been an issue for many
years, and still persists today. Further research and publication of data highlighting this under-representation would
help increase awareness. The recommendations and guidance from bodies such as American Society of Clinical
Oncology, the FDA and other organizations, along with educational materials for clinicians and researchers should
help overcome challenges to Phase I trial enrollment. Patients may also become more aware of available options
through greater interaction with clinicians and researchers from under-represented groups, which may help build
trust and confidence in trial participation.
Summary points
• Clinical trials provide answers on the safety and efficacy of novel therapeutics, inform medical professionals on
the use of new therapeutic agents, and enable global regulatory agencies to make approval decisions.
• Clinical trials should enroll patients that are representative of the demographics of the population to be treated.
However, the literature reports disparities in trial participation, particularly in the inclusion of racial and ethnic
minorities.
• This study investigated demographic representation in Phase I oncology clinical trials of biopharmaceutical
oncology agents published during 2019, with a particular focus on US-based trials.
• We employed a standardized approach to identify, describe, report and interpret published evidence in
adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol guidelines.
• Globally, race or ethnicity was identified in 220 (58.8%) of 374 Phase I oncology clinical trials assessed in this
review, with a total of 9972 participants.
• Among the 220 clinical trials with demographic data, the population was predominantly White/Caucasian
(62.2%), followed by Asian (29.9%), Black (3.9%) and Hispanic/Latino participants (1.2%) were
under-represented.
• The distribution of patients in US trials was heavily skewed toward White/Caucasian (84.2%), with minimal
representation of Blacks/African–Americans (7.3%), Asians (3.4%) and Hispanics/Latinos (2.8%).
• Many current barriers to participation may contribute to this disparity, such as the types of institutions where
patients receive care, health insurance coverage/restrictions and certain social determinants of health. As a result,
Phase I oncology trials are not always representative of the general population, and this may perpetuate health
disparities.
• Recruitment and retention of under-represented groups in Phase I oncology clinical trials is essential to ensure the
demographics of participants reflect the wider population at large. Focused strategies to recruit representative
populations are needed, and further research is required in order to understand any barriers to participation.
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